Vipidia

RSS

alogliptin benzoate

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Vipidia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vipidia.

For practical information about using Vipidia, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 03/12/2018

Authorisation details

Product details
Name
Vipidia
Agency product number
EMEA/H/C/002182
Active substance
alogliptin
International non-proprietary name (INN) or common name
alogliptin benzoate
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10BH04
Publication details
Marketing-authorisation holder
Takeda Pharma A/S
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
18/09/2013
Contact address
Langebjerg 1
DK-4000 Roskilde
Denmark

Product information

24/05/2018 Vipidia - EMEA/H/C/002182 - R/0019

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Drugs used in diabetes

  • dipeptidyl peptidase 4 (DPP 4) inhibitors

Therapeutic indication

Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

Assessment history

How useful was this page?

Add your rating